

# Sickle Cell Disease Treatment Market - 2024-2033

<https://marketpublishers.com/r/S9EAD17CE866EN.html>

Date: January 2026

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: S9EAD17CE866EN

## Abstracts

The Sickle Cell Disease Treatment Market was valued at US\$ 2.99 billion in 2024 and is anticipated to reach US\$ 9.97 billion by 2033, at a CAGR of 0.148 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Sickle Cell Disease Treatment Market.

This report delivers a comprehensive overview of the Sickle Cell Disease Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Sickle Cell Disease Treatment Market. The Sickle Cell Disease Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Sickle Cell Disease Treatment Market Scope:

### Major Highlights

This report delivers a comprehensive overview of the Sickle Cell Disease Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Sickle Cell Disease Treatment Market. The Sickle Cell Disease Treatment Market size, estimates, and

forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

#### Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

#### Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

#### Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies



## Contents

### **1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET INTRODUCTION AND SCOPE**

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

### **2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET EXECUTIVE INSIGHTS AND KEY TAKEAWAYS**

### **3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS**

- 3.1. Key Trends and Future Projections

### **4. SNIPPET BY DISEASE TYPE**

- 4.1. Snippet by Treatment Type
- 4.2. Snippet by Region

### **5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET DYNAMICS**

- 5.1. Impacting Factors
  - 5.1.1. Drivers
    - 5.1.1.1. Rising prevalence of sickle cell disease
    - 5.1.1.2. Rising novel drug development activities and regulatory approvals
  - 5.1.2. Restraints
    - 5.1.2.1. Product recalls and discrepancies in distribution

### **6. XX**

- 6.1. Opportunities

### **7. IMPACT ANALYSIS**

### **8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET INDUSTRY ANALYSIS**

- 8.1. Epidemiology

- 8.2. Market Leaders and Pioneers
- 8.3. Latest Developments and Breakthroughs
- 8.4. Pipeline Analysis
- 8.5. Regulatory and Reimbursement Landscape
- 8.6. Pricing Analysis
- 8.7. Porter's Five Forces Analysis
- 8.8. Patent Analysis
- 8.9. SWOT Analysis
- 8.10. Unmet Needs and Gaps
- 8.11. Recommended Strategies for Market Entry and Expansion
- 8.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts

## **9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET BY DISEASE TYPE**

- 9.1. Introduction
  - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  - 9.1.2. Market Attractiveness Index, By Disease Type
- 9.2. Hemoglobin SS (HbSS)\*
  - 9.2.1. Introduction
  - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Hemoglobin SC (HbSC)
- 9.4. Hemoglobin (HbS) Beta Thalassemia
- 9.5. Others

## **10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET BY TREATMENT TYPE**

- 10.1. Introduction
  - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 10.1.2. Market Attractiveness Index, By Treatment Type
- 10.2. Pharmacotherapy\*
  - 10.2.1. Introduction
  - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Gene Therapy
- 10.4. Blood Transfusions
- 10.5. Bone Marrow Transplantation

## **11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET BY REGION**

- 11.1. Introduction
  - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  - 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
  - 11.2.1. Introduction
  - 11.2.2. Key Region-Specific Dynamics
  - 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  - 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.2.5.1. The U.S.
    - 11.2.5.2. Canada
    - 11.2.5.3. Mexico
- 11.3. Europe
  - 11.3.1. Introduction
  - 11.3.2. Key Region-Specific Dynamics
  - 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  - 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.3.5.1. Germany
    - 11.3.5.2. U.K.
    - 11.3.5.3. France
    - 11.3.5.4. Spain
    - 11.3.5.5. Italy
    - 11.3.5.6. Rest of Europe
- 11.4. South America
  - 11.4.1. Introduction
  - 11.4.2. Key Region-Specific Dynamics
  - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.4.5.1. Brazil
    - 11.4.5.2. Argentina
    - 11.4.5.3. Rest of South America
- 11.5. Asia-Pacific
  - 11.5.1. Introduction
  - 11.5.2. Key Region-Specific Dynamics
  - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 11.5.5.1. China
- 11.5.5.2. India
- 11.5.5.3. Japan
- 11.5.5.4. South Korea
- 11.5.5.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
  - 11.6.1. Introduction
  - 11.6.2. Key Region-Specific Dynamics
  - 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  - 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

## **12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET COMPETITIVE LANDSCAPE**

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

## **13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET COMPANY PROFILES**

Key Market Players

### **1. NOVARTIS AG\***

- 1.1. Company Overview
  - 1.1.1. Product Portfolio
    - 1.1.1.1. Product Description
    - 1.1.1.2. Product Key Performance Indicators (KPIs)
    - 1.1.1.3. Historic and Forecasted Product Sales
    - 1.1.1.4. Product Sales Volume
  - 1.1.2. Financial Overview
    - 1.1.2.1. Company Revenue
    - 1.1.2.2. Geographical Revenue Shares
    - 1.1.2.3. Revenue Forecasts
  - 1.1.3. Key Developments
    - 1.1.3.1. Mergers & Acquisitions
    - 1.1.3.2. Key Product Development Activities
    - 1.1.3.3. Regulatory Approvals, etc.

- 1.1.4. SWOT Analysis
  - 1.2. Vertex Pharmaceuticals Incorporated.
  - 1.3. bluebird bio, Inc.
  - 1.4. Emmaus Medical, Inc.
  - 1.5. Bristol-Myers Squibb Company.
  - 1.6. CHIESI FARMACEUTICI S.p.A.
  - 1.7. Teva Pharmaceutical Industries Ltd.
- \* Similar data will be provided for each market player.
- Emerging Market Players

## **1. AGIOS PHARMACEUTICALS, INC.\***

- 1.1. Pipeline Products Description
    - 1.1.1. Product Key Performance Indicators (KPIs)
    - 1.1.2. Key Activities
    - 1.1.3. Market Entry Timelines
    - 1.1.4. Product Penetration Rate
    - 1.1.5. Sales Estimation and Projections
  - 1.2. Beam Therapeutics.
  - 1.3. Editas Medicine
  - 1.4. Novo Nordisk A/S
  - 1.5. Pfizer Inc.
- \* Similar data will be provided for each market player.
- LIST NOT EXHAUSTIVE

## **1. APPENDIX**

- 1.1. About Us and Services
- 1.2. Contact Us

## I would like to order

Product name: Sickle Cell Disease Treatment Market - 2024-2033

Product link: <https://marketpublishers.com/r/S9EAD17CE866EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S9EAD17CE866EN.html>